Robinson Value Management’s Teva Pharmaceuticals TEVA Stock Holding History

Robinson Value Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-141	Closed	-$3K	–	78
2018 Q2	$3K	Buy	+141	New	+$2.88K	﹤0.01%	77
2017 Q4	–	Sell	-81,441	Closed	-$1.43M	–	66
2017 Q3	$1.43M	Sell	81,441 -2,583	-3%	-$58.1K	1.32%	35
2017 Q2	$2.79M	Buy	84,024 +2,285	+3%	+$70.7K	2.61%	9
2017 Q1	$2.62M	Buy	81,739 +1,425	+2%	+$48.6K	2.43%	11
2016 Q4	$2.91M	Buy	+80,314	New	+$3.21M	2.74%	8

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Robinson Value Management's TEVA Position: Q3 2018 in Review

Robinson Value Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2018, closing a stake of 141 shares — an estimated $3K sold.

Robinson Value Management first reported a position in TEVA in Q4 2016 and held it in 5 quarters. The position peaked at $2.91M in Q4 2016. 556 funds tracked by Wall St. Rank hold TEVA as of Q3 2018.

Robinson Value Management reported no remaining Teva Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Robinson Value Management sold 141 Teva Pharmaceuticals shares in Q3 2018, an estimated $3K.
Robinson Value Management first reported a position in Teva Pharmaceuticals in Q4 2016 and held it in 5 quarters.
Robinson Value Management's Teva Pharmaceuticals position peaked at $2.91M in Q4 2016.
556 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2018.

Based on Robinson Value Management's 13F filing for Q3 2018, filed 2 Nov 2018.